NCT04625699 2023-06-06Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentColumbia UniversityPhase 2 Withdrawn
NCT03130764 2017-12-06Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLCColumbia UniversityPhase 2 Withdrawn